Howard D. Homesley

16.0k total citations · 2 hit papers
173 papers, 11.2k citations indexed

About

Howard D. Homesley is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Surgery. According to data from OpenAlex, Howard D. Homesley has authored 173 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Reproductive Medicine, 72 papers in Obstetrics and Gynecology and 49 papers in Surgery. Recurrent topics in Howard D. Homesley's work include Ovarian cancer diagnosis and treatment (83 papers), Endometrial and Cervical Cancer Treatments (64 papers) and Cervical Cancer and HPV Research (23 papers). Howard D. Homesley is often cited by papers focused on Ovarian cancer diagnosis and treatment (83 papers), Endometrial and Cervical Cancer Treatments (64 papers) and Cervical Cancer and HPV Research (23 papers). Howard D. Homesley collaborates with scholars based in United States, Japan and Czechia. Howard D. Homesley's co-authors include Brian N. Bundy, William T. Creasman, Mark F. Brady, John A. Blessing, C. Paul Morrow, James E. Graham, Paul B. Heller, Robert A. Burger, Bradley J. Monk and J.T. Thigpen and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Howard D. Homesley

171 papers receiving 10.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

2011 1.6k citations Robert A. Burger, Mark F. Brady et al. profile →
Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group study

1987 1.5k citations Brian N. Bundy, Howard D. Homesley et al. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Howard D. Homesley United States	47	6.4k	5.8k	2.9k	2.5k	1.7k	173	11.2k
Karl C. Podratz United States	67	7.2k 1.1×	7.2k 1.2×	3.5k 1.2×	3.0k 1.2×	1.4k 0.9×	264	13.9k
Philip J. DiSaia United States	50	3.7k 0.6×	4.7k 0.8×	2.7k 0.9×	1.8k 0.7×	1.1k 0.7×	238	8.9k
Angiolo Gadducci Italy	55	5.0k 0.8×	3.9k 0.7×	2.3k 0.8×	2.3k 0.9×	1.0k 0.6×	374	9.6k
J.T. Thigpen United States	36	3.6k 0.6×	4.9k 0.8×	2.5k 0.8×	2.1k 0.8×	1.3k 0.8×	175	8.5k
Costantino Mangioni Italy	49	3.9k 0.6×	4.3k 0.7×	2.0k 0.7×	1.8k 0.7×	841 0.5×	174	8.2k
John T. Soper United States	51	3.5k 0.5×	3.6k 0.6×	1.5k 0.5×	1.9k 0.8×	826 0.5×	191	8.3k
Domenica Lorusso Italy	46	4.9k 0.8×	3.3k 0.6×	2.6k 0.9×	3.6k 1.4×	1.2k 0.7×	521	9.7k
Robert A. Burger United States	48	9.1k 1.4×	3.7k 0.6×	4.4k 1.5×	4.6k 1.8×	1.9k 1.1×	202	14.8k
Mark F. Brady United States	42	8.4k 1.3×	3.9k 0.7×	3.7k 1.2×	3.7k 1.5×	1.6k 1.0×	111	12.0k
J. Taylor Wharton United States	48	2.7k 0.4×	2.9k 0.5×	2.5k 0.9×	2.0k 0.8×	836 0.5×	166	7.5k

Countries citing papers authored by Howard D. Homesley

Since Specialization

Citations

This map shows the geographic impact of Howard D. Homesley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard D. Homesley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard D. Homesley more than expected).

Fields of papers citing papers by Howard D. Homesley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Howard D. Homesley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard D. Homesley. The network helps show where Howard D. Homesley may publish in the future.

Co-authorship network of co-authors of Howard D. Homesley

This figure shows the co-authorship network connecting the top 25 collaborators of Howard D. Homesley. A scholar is included among the top collaborators of Howard D. Homesley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Howard D. Homesley. Howard D. Homesley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Burger, Robert A., Mark F. Brady, Michael A. Bookman, et al.. (2012). Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. Obstetrical & Gynecological Survey. 67(5). 289–290. 197 indexed citations

2.

Kunos, Charles A., Fiona Simpkins, Heidi Gibbons, Chunqiao Tian, & Howard D. Homesley. (2009). Radiation Therapy Compared With Pelvic Node Resection for Node-Positive Vulvar Cancer. Obstetrics and Gynecology. 114(3). 537–546. 121 indexed citations

3.

Homesley, Howard D., Virginia L. Filiaci, Susan K. Gibbons, et al.. (2008). A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecologic Oncology. 112(3). 543–552. 153 indexed citations

4.

Homesley, Howard D., Virginia L. Filiaci, Maurie Markman, et al.. (2007). Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group Study. Journal of Clinical Oncology. 25(5). 526–531. 170 indexed citations

5.

Moll, Stephan, et al.. (2006). Phase II Trial of Alfimeprase, a Novel-Acting Fibrin Degradation Agent, for Occluded Central Venous Access Devices. Journal of Clinical Oncology. 24(19). 3056–3060. 36 indexed citations

6.

Sutton, Gregory P., Brian N. Bundy, Tapan Kumar Roy, et al.. (2005). Whole Abdominal Radiotherapy in the Adjuvant Treatment of Patients With Stage III and IV Endometrial Cancer: A Gynecology Oncology Group Study. Obstetrical & Gynecological Survey. 60(10). 648–649. 13 indexed citations

7.

Sutton, Gregory P., Brian N. Bundy, Tapan Kumar Roy, et al.. (2005). Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: A phase II study of the Gynecologic Oncology Group. Gynecologic Oncology. 100(2). 349–354. 69 indexed citations

8.

Homesley, Howard D., Guy M. Boike, & Gregory Spiegel. (2004). Feasibility of laparoscopic management of presumed stage I endometrial carcinoma and assessment of accuracy of myoinvasion estimates by frozen section: a gynecologic oncology group study. International Journal of Gynecological Cancer. 14(2). 341–347. 25 indexed citations

9.

Homesley, Howard D.. (1995). Management of vulvar cancer. Cancer. 76(S10). 2159–2170. 34 indexed citations

10.

Homesley, Howard D., Irving Shemano, Richard A. Gams, et al.. (1993). Antiestrogenic Potency of Toremifene and Tamoxifen in Postmenopausal Women. American Journal of Clinical Oncology. 16(2). 117–122. 25 indexed citations

11.

Homesley, Howard D., Robert V. O’Toole, Barth Hoogstraten, et al.. (1992). Randomized Comparison of Cisplatin plus Epirubicin or Doxorubicin for Advanced Epithelial Ovarian Carcinoma. American Journal of Clinical Oncology. 15(2). 129–134. 22 indexed citations

12.

Welander, Charles E., Howard D. Homesley, & Rolland J. Barrett. (1991). Combined interferon alf a and doxorubicin in the treatment of advanced cervical cancer. American Journal of Obstetrics and Gynecology. 165(2). 284–291. 5 indexed citations

13.

Homesley, Howard D., et al.. (1989). CA-125 Values Predictive of Clinical Response during Second-Line Chemotherapy for Epithelial Ovarian Cancer. American Journal of Clinical Oncology. 12(2). 106–109. 8 indexed citations

14.

Sutton, Gregory P., John A. Blessing, Howard D. Homesley, M L Berman, & John H. Malfetano. (1989). Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.. Journal of Clinical Oncology. 7(11). 1672–1676. 94 indexed citations

15.

Welander, Charles E., Howard D. Homesley, Steven D. Reich, & Elizabeth Levin. (1988). A Phase II Study of the Efficacy of Recombinant Interferon Gamma in Relapsing Ovarian Adenocarcinoma. American Journal of Clinical Oncology. 11(4). 465–469. 30 indexed citations

16.

Sedlis, Alexander, Howard D. Homesley, Brian N. Bundy, et al.. (1987). Positive groin lymph nodes in superficial squamous cell vulvar cancer. American Journal of Obstetrics and Gynecology. 156(5). 1159–1164. 51 indexed citations

17.

Sedlis, Alexander, Howard D. Homesley, Brian N. Bundy, et al.. (1987). Positive groin lymph nodes in superficial squamous cell vulvar cancer. American Journal of Obstetrics and Gynecology. 156(5). 1159–1164. 112 indexed citations

18.

Kutteh, William H., Charles E. Welander, Howard D. Homesley, & George J. Doellgast. (1985). Autologous antibodies eluted from membrane fragments isolated from the effusions of human ovarian epithelial neoplasms. American Journal of Obstetrics and Gynecology. 153(2). 124–129. 3 indexed citations

19.

Galle, Peter R., Howard D. Homesley, & Alfred L. Rhyne. (1978). Reassessment of the surgical scrub.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 147(2). 215–8. 61 indexed citations

20.

Galle, Peter R., Hyman B. Muss, Katherine McGrath, John J. Stuart, & Howard D. Homesley. (1978). Thrombocytopenia in two patients treated with low-dose heparin.. PubMed. 52(1 Suppl). 9S–11S. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact